Credits Earned (2024) Crédits obtenus

Redeem Prepaid Membership

Tools for Practice Outils pour la pratique


#30 Iron Deficiency Anemia in the Elderly: How much iron is enough?


CLINICAL QUESTION
QUESTION CLINIQUE
In elderly adults with iron deficiency anemia (IDA), what is the appropriate dose of iron?


BOTTOM LINE
RÉSULTAT FINAL
In elderly patients with iron deficiency anemia, low doses of iron raise hemoglobin similar to higher doses with considerably less adverse events in most patients. Options for dosing include ½ of a 300 mg ferrous gluconate per day or 2.5 mL of Fer-In-Sol syrup a day. Clinicians should work-up the cause of anemia as appropriate.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
A Randomized Controlled Trial (RCT) addresses this question. 
  • 90 anemic patients (mean age 85, 59% female) randomized to 15 mg, 50 mg or 150 mg of elemental iron per day.1   
    • At two months, there was no difference among the groups in hemoglobin or serum ferritin. 
      • Hemoglobin increased 14 g/dL in all three groups. 
    • Adverse events were significantly more common at higher doses. 
      • Number Needed to Harm (NNH) for 150 mg versus 15 mg. 
        • Abdominal cramps: NNH=2. 
        • Nausea/vomiting: NNH=2. 
        • Constipation: NNH=5. 
        • Drop-out due to adverse events: NNH=5. 
Context:   
  • IDA is common in the elderly.2 
    • >10% have IDA at age 65 and >20% have IDA at age 85. 
  • IDA in older patients requires work-up for potential causes, including gastrointestinal malignancy.3   
  • In the very elderly (age 85), IDA carries an increased risk of mortality, hazards ratio 1.41 (1.13 to 1.76), in addition to the condition causing anemia.4 
  • In pregnant5,6 and non-pregnant young women7 recommendations are difficult. 
    • Low dose reduced adverse events6,8 but did not improve ferritin5,7 and hemoglobin6 as much as high dose.  High-dose (≥60 mg/day) also decreased the risk of low birth weight.9,10   
  • Iron is commercially available in 300 mg tablets. For dose conversion: 
    • Ferrous fumarate 300 mg = 99 mg elemental iron. 
    • Ferrous sulfate 300 mg = 60 mg elemental iron. 
    • Ferrous gluconate 300 mg = 35 mg elemental iron. 
  • For dosing to 15 mg of elemental iron per day consider: 
    • ½ of ferrous gluconate 300 mg tablet (or one every other day). 
    • 2.5 mL of Fer-In-Sol syrup a day or one dropper (1 mL) of the Fer-In-Sol drops daily. 
  • Taking iron on an empty stomach improves absorption.5 
updated jan 19 2018 by ricky


Latest Tools for Practice
Derniers outils pour la pratique

#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?

What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
Read Lire 0.25 credits available Crédits disponibles

#377 How to slow the flow IV: Combined oral contraceptives

In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
Read Lire 0.25 credits available Crédits disponibles

#376 Testosterone supplementation for cis-gender men: Let’s (andro-)pause for a moment (Update)

What are the benefits and harms of testosterone supplementation in healthy cis-gender men or those with age-related low testosterone?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • Candra Cotton BSc Pharm
  • G. Michael Allan MD CCFP

1. Rimon E, Kagansky N, Kagansky M, et al. Am J Med. 2005; 118:1142-7.

2. Guralnik JM, Eisenstaedt RS, Ferrucci L, et al. Blood. 2004; 104:2263-8.

3. Ioannou GN, Rockey DC, Bryson CL, et al. Am J Med. 2002; 113:276-80.

4. den Elzen WP, Willems JM, Westendorp RG, et al. CMAJ. 2009; 181:151-7.

5. Milman N, Bergholt T, Eriksen L, et al. Acta Obstet Gynecol Scand. 2005; 84:238-47.

6. Zhou SJ, Gibson RA, Crowther CA, et al. Eur J Clin Nutr. 2009; 63:183-90.

7. Kianfar H, Kimiagar M, Ghaffarpour M. Int J Vitam Nutr Res. 2000; 70(4):172-7.

8. Reveiz L, Gyte GML, Cuervo LG, et al. Cochrane Database of System Rev. 2011; 10:CD003094.

9. Haider BA, Olofin I, Wang M, et al. BMJ. 2013; 346:f3443.

10. Peña-Rosas JP, De-Regil LM, Dowswell T, et al. Cochrane Database System Rev. 2012; 12:CD004736.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.

Most recent review: 19/01/2018

By: Ricky D. Turgeon BSc(Pharm) ACPR PharmD

Comments:

Evidence Updated: None; Bottom Line: Unchanged.

Learning at a glance
Yearly credits
Acquired ()
Your content by topic
Cardiology Dermatology Emergency
My Bookmarks